Aktuelle Rheumatologie 2020; 45(04): 341-347
DOI: 10.1055/a-0629-8340
Original Article

KIAA1199 Biomarker and Ultrasonographic Findings in Rheumatoid Arthritis Patients and their Correlation with Disease Activity

KIAA1199-Biomarker und ultrasonografische Befunde bei Patienten mit rheumatoider Arthritis und Korrelation dieser Ergebnisse mit der Krankheitsaktivität
Zahraa Ibrahim Selim
1   Faculty of medicine Assuit university, rhematology and rehabilitation, Assuit, Egypt
,
Eman H El-Hakeim
2   Rheumatology and Rehablitation Department, Assiut, Assiut University Hospital, Egypt
,
Eman Ahmed Hamed Omran
3   Faculty of Medicine, Rheumatology, Rehabilitation and Physical Medicine, Assiut University, Assiut, Egypt
,
Naglaa K. Idriss
4   Medical Biochemictry, Assuit University, Assuit, Egypt
,
Marwa A. Gaber
4   Medical Biochemictry, Assuit University, Assuit, Egypt
,
Sylvia V Ross
5   Rheumatology, Rehabilitation, Physical Medicine, Assuit university, Assuit, Egypt
› Author Affiliations
Funding No external funding, the study was done and covered by institutional resources.

Abstract

Introduction Rheumatoid arthritis (RA) is an autoimmune disease that affects multiple joints causing joint destruction. KIAA1199 is a novel angiogenic biomarker derived from fibroblast-like synoviocytes (FLS) it has a role in acceleration and proliferation of FLS and activation of angiogenic signaling pathways leading to erosion of cartilage and bone. Musculoskeletal ultrasound (MUSU) and Power Doppler (PDUS) directly visualizing the synovial membrane vessels, which is important in providing very early information on the changes in synovitis activity during the course of the inflammatory joint disease

Objective To assess the serum level of angiogenic biomarker KIAA1199 in RA patients and its correlation with MSUS, PDUS findings, and the disease activity Patients and methods: Fifty RA patients and 40 healthy control persons age and sex-matched were recruited in this study, KIAA1199 was assessed in the serum of patients and controls, MSUS and PDUS were done for the wrist, elbow, and knee joints for all RA patients

Results Serum KIAA1199 level was significantly higher among RA patients 4.36±1.22 ng/dl compared to control group 2.87±0.51 ng/dl (p<0.001). There was a highly significant correlation between KIAA1199 level and DAS28 (p=0.004), and there was a significant correlation between the PDUS with KIAA1199 level and DAS28 (p=0.001, 0.002 respectively) in wrist joints

Conclusion KIAA1199 is a new pathway that enhancing cell proliferation and angiogenesis. Serum KIAA1199 level may be a useful biomarker for RA activity, and therapeutic target in RA. PDUS correlates significantly with clinical findings and novel angiogenic biomarker in RA patients.

Zusammenfassung

Einführung Die rheumatoide Arthritis (RA) ist eine Autoimmunerkrankung, die multiple Gelenke betrifft und eine Gelenkdestruktion verursacht. KIAA1199 ist ein neuer angiogenetischer Biomarker, der aus fibroblastenartigen Synoviozyten (FLS) gewonnen wird. Er spielt eine Rolle bei der Beschleunigung der Proliferation von FLS und der Aktivierung angiogenetischer Signalwege, die zur Erosion von Knorpel und Knochen führen. Muskuloskelettaler Ultraschall (MUSU) und Power-Doppler-Ultraschall (PDUS) ermöglichen eine direkte Darstellung der Gefäße in der Synovialmembran und liefern somit wichtige, sehr frühzeitige Informationen über Veränderungen der synovitischen Aktivität im Verlauf der entzündlichen Gelenkerkrankung.

Ziel Beurteilung des Serumspiegels des angiogenetischen Biomarkers KIAA1199 bei RA-Patienten und dessen Korrelation mit MSUS- und PDUS-Befunden und der Krankheitsaktivität.

Patienten und Methoden Beurteilung des Serumspiegels des angiogenetischen Biomarkers KIAA1199 bei RA-Patienten und dessen Korrelation mit MSUS- und PDUS-Befunden und der Krankheitsaktivität. Es wurden fünfzig RA-Patienten und 40 gesunde Kontrollprobanden entsprechenden Alters und Geschlechts in diese Studie aufgenommen. Bei den Patienten und den Kontrollprobanden wurde der Serumspiegel von KIAA1199 gemessen. Bei allen RA-Patienten wurden MSUS- und PDUS-Untersuchungen der Handgelenke, Ellbogen- und Kniegelenke durchgeführt.

Ergebnisse Der Serumspiegel von KIAA1199 war bei den RA-Patienten signifikant höher (4,36±1,22 ng/dl) als in der Kontrollgruppe (2,87±0,51 ng/dl) (p<0,001). Es fanden sich eine hochsignifikante Korrelation zwischen dem KIAA1199-Spiegel und dem DAS28 (p=0,004) sowie eine signifikante Korrelation zwischen PDUS und KIAA1199-Spiegel bzw. PDUS und DAS28 (p=0,001 bzw. 0,002) bei den Handgelenken.

Schlussfolgerung KIAA1199 ist ein neuer Biomarker für eine erhöhte Zellproliferation und Angiogenese. Der Serumspiegel von KIAA1199 kann die RA-Aktivität aufzeigen und als therapeutisches Ziel bei RA dienen. PDUS korreliert signifikant mit den klinischen Befunden und dem neuen angiogenetischen Biomarker bei RA-Patienten.



Publication History

Article published online:
06 June 2018

© Georg Thieme Verlag KG
Stuttgart · New York

 
  • References

  • 1 Houri LE, Watad A, Whitby A. et al. Coexistence of Ischemic Heart Disease and Rheumatoid Arthritis Patients – a Case Control Study. Autoimmun Rev. 2016; 15: 393-396
  • 2 Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: Pathogenic and clinical significance. J Invest Med 1998; 46: 27-41
  • 3 Koch AE. Review: Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 1998; 41: 951-962
  • 4 Walsh DA. Angiogenesis and arthritis. Rheumatology 1999; 38: 103-112
  • 5 Hayes AJ. Angioneogenesis in rheumatoid arthritis. Lancet 1999; 354: 423-424
  • 6 Szekanecz Z, Koch AE. Mechanism of disease: Angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3: 635-643
  • 7 Veale D, Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: Potential for therapeutic targeting. BestPract Res Clin Rheumatol 2006; 20: 941-947
  • 8 Wang JG, Xu WD, Zhai WT. et al. Disorders in angiogenesis and redox pathways are main factors contributing to the progression of rheumatoid arthritis: A comparative proteomics study. Arthritis Rheum 2012; 64: 993-1004
  • 9 Yang X, Qiu P, Chen B. et al. KIAA1199 as a potential diagnostic biomarker of rheumatoid arthritis related to angiogenesis. Arthritis Res Ther 2015; 17: 140
  • 10 Abe S, Usami S, Nakamura Y. Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters’ cells and the fibrocytes, as the cause of non-syndromic hearing loss. J Hum Genet 2003; 48: 564-570
  • 11 Matsuzaki S, Tanaka F, Mimori K. et al. Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer. Ann Surg. Oncol 2009; 16: 2042-2051
  • 12 Tiwari A, Schneider M, Fiorino A. et al. Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors. PLoS One 2013; 8: e69473
  • 13 Naredo E, Bonilla G, Gamero F. et al. Assessment of inflammatory activity in rheumatoid arthritis: A comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005; 64: 375-381
  • 14 Joshua F, Edmonds J, Lassere M. Power Doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 2006; 36: 9910-9918
  • 15 Brown AK, Conaghan PG, Karim Z. et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-2967
  • 16 Szkudlarek M, Court-Payen M, Stranberg C. et al. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: A comparison with dynamic magnetic resonance imaging. Arthritis Rheum 2001; 44: 2018-2023
  • 17 Terslev L, Torp-Pedersen S, Savnik A. et al. Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: a comparative study. Arthritis Rheum 2003; 48: 2434-2441
  • 18 Saleem B, Brown AK, Quinn M. et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 2012; 71: 1316-1321
  • 19 Vreju FL, Ciurea M, Rosu A. et al. Power Doppler sonography, a non-invasive method of assessment of the synovial inflammation in patients with early rheumatoid arthritis. Rom J Morphol Embryol 2011; 52: 637-643
  • 20 Foltz V, Gandjbakhch F, Etchepare F. et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 2012; 64: 67-76
  • 21 Aletaha D, Neogi T, Silman AJ. et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann. Rheum Dis 2010 69: 1580-1588
  • 22 Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): Analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumato 2001; 28: 982-989
  • 23 Mandl P, Naredo E. Wakefield et al. OMERACT Ultrasound Task Force. A systematic literature review analysis of ultrasound joint count and scoring systems to assess synovitis in rheumatoid arthritis according to the OMERACT filter. J Rheumatol 2011; 38: 2055-2062
  • 24 Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: ‘vascular rheumatology’. Arthritis Res Ther 2008; 10: 224
  • 25 Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 2006; 18: 268-276
  • 26 Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289-295
  • 27 Szekanecz Z, Besenyei T, Paragh G. et al. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009; 42: 563-573
  • 28 Lee S, Chen TT, Barber CL. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703
  • 29 Yoshida H, Nagaoka A, Kusaka-Kikushima A. et al. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc Natl Acad Sci USA 2013; 110: 5612-5617
  • 30 Terao C, Hashimoto M, Yamamoto K. et al. Three Groups in the 28 Joints for Rheumatoid Arthritis Synovitis – Analysis Using More than 17,000 Assessments in the KURAMA Database. PLoS ONE 2013; 8: e59341 10. 1371
  • 31 Vreju Fl, Ciurea M, Rosu A. et al. Power Doppler sonography, a non-invasive method of assessment of the synovial inflammation in patients with early rheumatoid arthritis. Rom J Morphol Embryol 2011; 52: 637-643
  • 32 Kelly S, Bombardieri M, Humby F. et al. Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early Rheumatoid Arthritis: an observational study. Arthritis Res Ther 2015; 17: 58
  • 33 Kawashiri SY, Kawakami A, Iwamoto N. et al. The powerDoppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of plasma biomarkers in patients with rheumatoid arthritis. Rheumatology 2011; 50: 962-965
  • 34 Naredo E, Rodríguez M, Campos C. et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59: 515-522
  • 35 Dougados M, Jousse-Joulin S, Mistretta F. et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicenter study of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 828-833
  • 36 Bhasin S, Cheung P. The Role of Power Doppler Ultrasonography as Disease Activity Marker in Rheumatoid Arthritis. Disease Markers www.Hindawi.com 2015 ID 325909, 9 pages
  • 37 Ohrndorf S, Backhaus M. Pro musculoskeletal ultrasonography in rheumatoid arthritis. Clin Exp Rheumatol 2015; 33: S50-S53
  • 38 Mandl P, Kurucz R, Niedermayer D. et al. Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. Rheumatology (Oxford) 2014; 53: 2136-2142